European journal of haematology · 2026
Advances and Challenges in the Multidisciplinary Treatment of Retroperitoneal Infantile Fibrosarcoma in Early Life.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Brunetti Gaia, Zarfati Angelo, Persano Giorgio, Milano Giuseppe Maria, Russo Ida, Natali Gian Luigi, Alaggio Rita, Crocoli Alessandro, Grimaldi Chiara
Аннотация
BACKGROUND AND AIMS: Retroperitoneal Infantile Fibrosarcoma (RIFS) is a rare, locally aggressive pediatric soft tissue tumor. Its retroperitoneal location poses challenges due to proximity and potential invasion of critical structures such as the inferior vena cava (IVC). This study aims to illustrate the range of multidisciplinary management strategies and evolving therapeutic approaches.
METHODS: We conducted a retrospective case series of infants diagnosed with RIFS and treated at our tertiary center. Clinical presentation, imaging findings, histopathology, treatment modalities (including chemotherapy, surgery, interventional radiology, targeted therapies), and follow-up data were analyzed.
RESULTS: Three infants with histologically confirmed RIFS were identified, with a median age at diagnosis of 2 months (range: 0-8 months). Diagnosis was established through open surgical biopsy. Management was individualized and multimodal, including neoadjuvant chemotherapy, surgical resection, interventional radiology procedures for symptom control, and, in the most recent case, targeted molecular therapy guided by genetic profiling.
CONCLUSIONS: Management of RIFS has significantly evolved over the last decade. Advances in surgical techniques combined with the integration of interventional radiology and novel targeted therapies allow a nuanced balance between maximizing oncological control and minimizing surgical morbidity. Multidisciplinary individualized treatment is essential to optimize outcomes in this rare and challenging pediatric tumor.
METHODS: We conducted a retrospective case series of infants diagnosed with RIFS and treated at our tertiary center. Clinical presentation, imaging findings, histopathology, treatment modalities (including chemotherapy, surgery, interventional radiology, targeted therapies), and follow-up data were analyzed.
RESULTS: Three infants with histologically confirmed RIFS were identified, with a median age at diagnosis of 2 months (range: 0-8 months). Diagnosis was established through open surgical biopsy. Management was individualized and multimodal, including neoadjuvant chemotherapy, surgical resection, interventional radiology procedures for symptom control, and, in the most recent case, targeted molecular therapy guided by genetic profiling.
CONCLUSIONS: Management of RIFS has significantly evolved over the last decade. Advances in surgical techniques combined with the integration of interventional radiology and novel targeted therapies allow a nuanced balance between maximizing oncological control and minimizing surgical morbidity. Multidisciplinary individualized treatment is essential to optimize outcomes in this rare and challenging pediatric tumor.